The COVID-19 pandemic has impacted the lives of millions of people around the world. From major pharmaceutical companies to smaller startups, professionals in the medical field have been arduously working to find ways to prevent its spread as well as looking for effective treatment solutions. As COVID-19 primarily affects the respiratory system, direct administration of drugs in the respiratory tract is seen as one of the most effective treatment routes. 

HCmed is ready to join the fight. Our mesh nebulizers are highly efficient customizable devices that deliver drugs deep into the lungs. Moreover, our technology allows the nebulization of biologic and high viscosity drugs, making the use of our mesh nebulizers ideal for treatments involving antibodies, mRNA, and other formulations of this type.

In order to partner up with companies that are developing inhaled formulations to treat COVID-19, HCmed is offering free of charge Aerodynamic Particle Size Distribution (APSD) pretesting analysis to evaluate aerosol characterization of nebulized formulations until August 31, 2020. 

We hope this initiative can create new collaborations that will serve as a vehicle to develop effective treatment options and help in the fight against COVID-19. For more information contact us visiting our newly redesigned website www.hcmed-inno.com or via email at info@hcmed-inno.com.
 

---